Novo Nordisk reports child obesity trial results
Novo Nordisk (NYSE:NVO) reported phase 3 STEP Young trial results showing once-weekly semaglutide plus lifestyle modification reduced BMI more than placebo in 165 children aged 6 to under 12 with obesity after 68 weeks.










